Ocular implant containing a tyrosine kinase inhibitor
US12357565B2 · kind B2 · utility
0Cited by
67References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 21, 2022 |
| Grant date | Jul 15, 2025 |
| Priority date | — |
| Expiry date | Aug 10, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K45/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.